Results 191 to 200 of about 48,471 (314)

A membranous nephropathy variant mimicking minimal change disease

open access: yesThe Journal of Pathology: Clinical Research, Volume 12, Issue 1, January 2026.
Abstract This study characterizes a novel disease pattern of membranous nephropathy (MN) that exhibits overlapping clinicopathological features with minimal change disease (MCD), termed ‘MCD‐like MN’. Patients with histologically confirmed MN showing sparse and segmental subepithelial electron‐dense deposits (EDD) but clinically resembling MCD were ...
Chuqi Pan   +8 more
wiley   +1 more source

Coexistence of SAPHO syndrome and IgG4-related disease with Upadacitinib. [PDF]

open access: yesClin Transl Immunology
Zhou H   +5 more
europepmc   +1 more source

Expert Perspective: Diagnosis and Treatment of Castleman Disease

open access: yesArthritis &Rheumatology, Volume 78, Issue 1, Page 12-25, January 2026.
Castleman disease (CD) is a major diagnostic challenge for rheumatologists. Unicentric CD (UCD) involves one enlarged lymph node region, whereas multicentric CD (MCD) involves multiple enlarged lymph node regions. Both UCD and MCD may exhibit a wide range of symptoms that overlap with other immune‐mediated conditions.
Luke Y. C. Chen   +2 more
wiley   +1 more source

IgG4-Related Disease With Lung and Kidney Involvement: A Case Report. [PDF]

open access: yesCureus
Sá Lima A   +3 more
europepmc   +1 more source

Add‐On Telitacicept Significantly Improves Outcome of Patients With Refractory Ocular Myasthenia Gravis a Real‐World Case Series

open access: yesBrain and Behavior, Volume 16, Issue 1, January 2026.
6/7 patients achieved CMI by the third follow‐up, sustained to the fourth follow‐up, and 4/6 reached MSE by the fifth follow‐up. First real‐world evidence of adding telitacicept efficacy in refractory ocular MG symptoms Abstract Introduction Refractory ocular myasthenia gravis (MG) represents a significant therapeutic challenge, as conventional ...
Jing Lin   +4 more
wiley   +1 more source

Rituximab and Intravenous Immunoglobulin (IVIG) for Refractory Eosinophilic Fasciitis: A Case Report

open access: yesClinical Case Reports, Volume 14, Issue 1, January 2026.
ABSTRACT Eosinophilic fasciitis (EF) is a rare condition with an unknown cause. This case study showed that a 40‐year‐old man with EF did not respond to standard treatments but improved after receiving rituximab and intravenous immunoglobulin (IVIG). Further studies are needed to confirm rituximab's effectiveness and long‐term safety for EF.
Maryam Sahebari   +4 more
wiley   +1 more source

Coexistence of nontuberculous mycobacterium and IgG4-related disease in a solitary pulmonary nodule

open access: gold, 2019
Kyungsoo Bae   +5 more
openalex   +1 more source

Home - About - Disclaimer - Privacy